Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Blood Test Evaluates Risk of Preeclampsia

By LabMedica International staff writers
Posted on 16 Nov 2011
A blood test can help to assess whether a pregnant woman who suffers from pregnancy-induced hypertension, so-called preeclampsia (PE), is at risk for an imminent delivery.

The concentration and ratio of two certain placenta-derived growth factors allows the identification of women at risk and is a reliable tool to discriminate between different types of pregnancy-related hypertensive disorders.

A team of scientists at the Charité University Medicine (Berlin, Germany) investigated 388 singleton pregnancies with normal pregnancy outcome, 164 with PE, 36 with gestational hypertension, and 42 with chronic hypertension. The measured the concentration of two certain placenta-derived growth factors, the soluble fms-like tyrosine kinase (sFlt-1) and placental growth factor (P1GF) in the participant's serum by commercial immunoassays.

The sFlt-1 and P1GF concentrations of each sample were determined in parallel. For each sample sFlt-1/P1GF ratio was calculated. Single measurements were performed for sFlt-1 and P1GF on the fully automated Roche Diagnostics (Penzberg, Germany) Elecsys system (Elecsys P1GF, human P1GF, and Elecsys sFlt-1). Patients with preeclampsia had a significantly increased sFlt-1/PlGF ratio as compared with controls and with patients with chronic and gestational hypertension in <34 weeks and ≥34 weeks. Time to delivery was significantly reduced in women with preeclampsia in the highest quartile of the sFlt-1/PlGF ratio. In patients with especially high test results, delivery resulted within 48 hours.

Preeclampsia is the most common of the dangerous pregnancy complications. It is characterized by elevated blood pressure, protein in the urine and accumulation of excess fluid beneath the skin. If not treated in time, preeclampsia may progress to eclampsia, characterized by tonic-clonic seizures that can possibly result in maternal and infant death.

The sFlt-1/PlGF ratio is a reliable tool to discriminate between different types of pregnancy-related hypertensive disorders and allows the identification of women at risk for imminent delivery. Stefan Verlohren, MD, lead author of the study said, "With this test we can assess the severity of preeclampsia and give a short-term prognosis of the disease course." Further studies will have to evaluate the test's validity in women who have an elevated risk of developing preeclampsia. The study was published online in July 2011, in the American Journal of Obstetrics & Gynecology.

Related Links:

Charité University Medicine


Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Malaria Test
STANDARD Q Malaria P.f/Pan Ag
New
Respiratory Bacterial Panel
Real Respiratory Bacterial Panel 2
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.